A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
New England Journal of Medicine · 12.02.2026 · 394 (7) · 647-657
DOI: 10.1056/nejmoa2510198 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 12.02.2026. Verfasst von Richard Lafayette und 21 weiteren Autor:innen. Beteiligte Einrichtung: Stanford University, Stanford, CA. Hauptthemen laut MEDLINE: Creatinine, Glomerulonephritis, IGA, Proteinuria, Recombinant Fusion Proteins. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Vera Therapeutics, Inc..
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Stanford University, Stanford, CA.
- Division of Nephrology, University of British Columbia, Vancouver, Canada.
- Vera Therapeutics, Brisbane, CA.
- University of Pennsylvania Perelman School of Medicine, Philadelphia.
- Faculty of Medicine, Division of Nephrology, Kocaeli University, Kocaeli, Turkey.
- Departments of Nephrology and Cardiology, RWTH Aachen University Hospital, Aachen, Germany.
ORCID-Profile: Beom Seok Kim
Förderung
- Vera Therapeutics, Inc.
Zitieren
APA
Lafayette, R., Barbour, S. J., Brenner, R. M., Campbell, K. N., Doan, T., Eren, N., Floege, J., Jha, V., Kim, B. S., Liew, A., Maes, B., Pal, A., Pecoits-Filho, R., Phoon, R. K. S., Rizk, D. V., Suzuki, H., Tesař, V., Trimarchi, H., Wei, X., …, & ORIGIN Phase 3 Trial Investigators (2026). A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. New England Journal of Medicine, 394(7), 647-657. https://doi.org/10.1056/nejmoa2510198
Vancouver
Lafayette R, Barbour SJ, Brenner RM, Campbell KN, Doan T, Eren N, et al. A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. New England Journal of Medicine. 2026;394(7):647-657. doi:10.1056/nejmoa2510198
BibTeX
@article{Lafayette2026,
author = {Lafayette, Richard and Barbour, Sean J and Brenner, Robert M and Campbell, Kirk N and Doan, Tom and Eren, Necmi and Floege, Jürgen and Jha, Vivekanand and Kim, Beom Seok and Liew, Adrian and Maes, Bart and Pal, Atanu and Pecoits-Filho, Roberto and Phoon, Richard K S and Rizk, Dana V and Suzuki, Hitoshi and Tesař, Vladimir and Trimarchi, Hernán and Wei, Xuelian and Zhang, Hong and Barratt, Jonathan and ORIGIN Phase 3 Trial Investigators, ORIGIN Phase 3 Trial Investigators},
title = {A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {7},
pages = {647--657},
doi = {10.1056/nejmoa2510198}
}
EUVIMED